Ironwood Pharmaceuticals Stock News

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1. Analyst Chris Howerton thinks Ardelyx "s

Ardelyx Inc (NASDAQ: ARDX ) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1 . Analyst Chris Howerton thinks Ardelyx "stands out" given that the Company has an approved IBS-C product, Isbrela, that will launch in April and whose commercial opportunity is validated by Linzess and Trulance. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD ) and AbbVie Inc''s (NYSE: ABBV ) Linzess achieved $1 billion in sales in 2021, while Salix Pharmaceuticals'' Trulance achieved … Full story available on Benzinga.com

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will be presenting at the following investor conferences: Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET Barclays Global Healthcare Conference on Tuesday, March 15, 2022 at 3:20 p.m. ET A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at www.ironwoodpharm

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will be presenting at the following investor conferences: Cowen

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates.

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD ) reported Q4 FY21 sales of $117.1 million , compared to $116.7 million in Q4 FY20, beating the consensus of $109.87 million. Ironwood recorded $113.7 million in collaboration revenue in Q4 related to sales of LINZESS in the U.S., a 2.7% Y/Y increase, and $3.4 million in royalties and other revenue. Total … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Amylyx Pharma

Ironwood Pharmaceuticals press release (IRWD): Q4 Non-GAAP EPS of $0.27 misses by $0.07.Revenue of $117.13M (+0.4% Y/Y) beats by $6.96M.Guidance: FY22 The company expects the…

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Thomas McCourt on Q4 2021 Results - Earnings Call Transcript

Companies Reporting Before The Bell • Palantir Technologies (NYSE: PLTR ) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. • Organon (NYSE: OGN ) is expected to report quarterly earnings at $1.24 per share on revenue of $1.57 billion. • Perella Weinberg Partners (NASDAQ: PWP ) is likely to report quarterly earnings at $0.30 per share on revenue of $193.75 million. • Navios Maritime Partners (NYSE: NMM ) is estimated to report quarterly earnings at $4.35 per share on revenue of $272.59 million. • Portland General Electric (NYSE: POR ) is likely to report quarterly earnings at $0.76 per share on revenue of $533.13 million. • Frontline (NYSE: FRO ) is estimated to report quarterly earnings at $0.13 per share on revenue of $111.30 million. • R1 RCM (NASDAQ: RCM ) is estimated to report quarterly earnings at $0.11 per share on revenue of $399.26 million. • Fiverr International (NYSE: FVRR ) is likely to report quarterly earnings at $0.04 per share on revenue of $76.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open.The consensus EPS Estimate is $0.34 (-5.6% Y/Y) and…